Navigation Links
Hagens Berman Sobol Shapiro Announces Proposed Class-Action Lawsuit Against CellCyte
Date:1/14/2008

SEATTLE, Jan. 14 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP (http://www.hbsslaw.com/ccyg.htm) today announced it filed a proposed class-action lawsuit in the United States District Court for the Western District of Washington at Seattle on behalf of purchasers of the common stock of CellCyte Genetics Corporation, ("CellCyte" or the "Company") (OTC Bulletin Board: CCYG) during the period between April 6, 2007 through and including January 9, 2008 (the "Class Period").

If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from January 14, 2008 -- or by March 14, 2008. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff's counsel, Steve Berman at 206-623-7292, or via e-mail at info@hbsslaw.com.

You can view a copy of the Complaint as filed online at http://www.hbsslaw.com/ccyg.htm. Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain a member of the proposed class.

The complaint alleges that during the Class Period CellCyte executives and business partners misled investors by publishing false information about the history and experience of the company's chief executive officer Gary A. Reys. Reys' background was called into question after published news reports called out alleged discrepancies relating to Reys' finance degree from the University of Washington, a CPA designation, ties to the Washington Society of Certified Public Accountants and a strong track record within the pharmaceutical industry.

According to the complaint CellCyte made misleading and false statements about Reys to potential investors and the SEC. These published statements had the cause and effe
'/>"/>

SOURCE Hagens Berman Sobol Shapiro LLP
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Hagens Berman Sobol Shapiro Investigating CellCyte
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2009)...onal Advisory Committee on Climate Change (NACCC) ...oject in collaboration with the Vanuatu Meteorolog...have generated preliminary climate change and sea ...or the country’s SNC reporting to the United...NFCCC). , Port Vila, Van...
(Date:11/27/2009)...wire-FirstCall/ -- Stallergenes has been,granted E...ts and children,through a Mutual Recognition Proce...has been marketed, was the reference Member state....a, Belgium, Bulgaria, Cyprus, the,Czech Republic, ..., Italy,Latvia, Lithuania, Luxembourg, Malta, the...
(Date:11/26/2009)...ion of ultrasmall transistors and more powerful co...ucting nanowires are closer to reality after a key...y and the University of California at Los Angeles....nowires with layers of different materials that ar...critical requirement for making efficient transist...
(Date:11/25/2009)...ire/ -- Biotech firm Replikins Ltd., which has ana...andemic through the prediction, outbreak, and prog...s latest biochemical analysis of the virus. The ne...e Flu") virus has dropped from its peak of 3.7 (s.... spring of 2009 to resting non-epidemic levels thi...
Breaking Biology Technology:Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5
...AMIR, Israel, Jan. 14 Shamir,Optical Industry Ltd...of,innovative products and technology to the progr...t its board of directors had declared a dividend,d...ion (approximately NIS,15.1 million based on the J...or approximately US$ 0.243 (approximately NIS 0.91...
...nd HAIKOU, China, Jan. 14 /Xinhua-PRNewswire-First...a,) (OTC Bulletin Board: CPHI),which develops, man...aceutical products in China, today announced that ...itiate a proactive and targeted investor,relations...I, and their,collective team, will be advising the...
...an. 14 Today, The Woodbridge Group announced,the ...industry,s highest,levels of "Green" Polyurethane ...e strategy, BioFoam, a patented technology, substi...ing of polyurethane products. This,earth-friendly ...,applications includes; seat cushions, seat fabric...
Other Biology Technology:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program 2China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program 3Woodbridge Offers the Broadest Range of BioFoam(TM) 'Green' Polyurethane Automotive Interior Applications 2
(Date:11/26/2009)...cus Aureus ) and other drug-resistant bacteria cou...totype devices have been developed to offer safe, ..., Two prototype devices have been developed: one...hands and feet) in hospitals and public spaces whe...to shoot bacteria-killing agents into infested chr...
(Date:11/25/2009)...ath Research Laboratory in the University of Haifa...stigious Johnson & Johnson Focused Funding grant f...damage in Parkinson,s disease. The award, which is...ovation and excellence in science, was announced i...h at an event at the Hyatt Regency Hotel in New Je...
(Date:11/24/2009)...ribed by traditional healers in Brazil to treat a ...to fever and flu. , Now for the first time, resea...cientifically prove the pain relieving properties ...mint. , Testing this ancient South American herb ... was able to show that when prepared as a ,tea, t...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Got a pain? -- Have a cup of Brazilian mint 2Celebrate June Is Dairy Month Beginning With Breakfast 48128 1Celebrate June Is Dairy Month Beginning With Breakfast 48128 2Windows XP Vista and Windows 7 Compatible Remote Control 4 0 Beta Released by IntelliAdmin LLC 48124 1Windows XP Vista and Windows 7 Compatible Remote Control 4 0 Beta Released by IntelliAdmin LLC 48124 2Afinitor 28R 29 Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma Leading to Phase III Trial 4554 1Afinitor 28R 29 Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma Leading to Phase III Trial 4554 2Afinitor 28R 29 Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma Leading to Phase III Trial 4554 3Afinitor 28R 29 Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma Leading to Phase III Trial 4554 4Afinitor 28R 29 Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma Leading to Phase III Trial 4554 5Afinitor 28R 29 Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma Leading to Phase III Trial 4554 6Afinitor 28R 29 Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma Leading to Phase III Trial 4554 7Afinitor 28R 29 Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma Leading to Phase III Trial 4554 8
... variations ensure that no two people are exactly .... Now, researchers have the tools and the knowled... cancer therapies, enabling them to create more ef...ized medicine. At the 2007 Annual Meeting of the A...rs present new biomarkers ?and techniques for dete...
...by" hysteria of the 1980s was greatly exaggerated,... disabling cognitive impairments -- attention defi.... , A recent study by investigators at the Vander...ent may help explain the long-term behavioral and ...osure to cocaine. In a recent issue of the Journal...
...e that nanoparticles, engineered materials about a...d lead to cancer, according to research presented ...tion for Cancer Research. , Nanoparticles are smal... yet they are large enough to cause trouble by int...t the University of Massachusetts say. Such nanop...
Other Biology News:Genes and biomarkers that allow doctors to choose the right therapy for the right patient 2Genes and biomarkers that allow doctors to choose the right therapy for the right patient 3Genes and biomarkers that allow doctors to choose the right therapy for the right patient 4Genes and biomarkers that allow doctors to choose the right therapy for the right patient 5Genes and biomarkers that allow doctors to choose the right therapy for the right patient 6Prenatal cocaine's lasting cellular effects 2Prenatal cocaine's lasting cellular effects 3Cancer tip -- Nanoparticles can damage DNA, increase cancer risk 2
...to Alpha unit with motorized heated lid and skirte...microarrays and chips. The four screw-down points ...sealing force of the motorized lid is set with sof...results. This interchangeable Moto Alpha unit func...
...e factor 15 (KLF15) KLF15 is a Cys2-His2 zinc fin...liver, kidneys, heart, and skeletal muscle. Acces...y produced in rabbits immunized with a synthetic p...th an internal ID of P03590 Reconstitution and St...
Affi-Prep Protein A Support, 25 ml from Bio-Rad
...ard is a new tuning and calibration standard for p...trometry. Accumix is a lyophilized 7-peptide stan...oth tuning and calibration of ion trap (i.e. Finni...ectrometers. Direct infusion of the Accumix pepti...
Biology Products: